Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2011

View Archived Issues

Johnson & Johnson recaps highlights of third quarter 2011

German research team presents new cyclin-dependent kinase 9 inhibitors

Ligand Pharmaceuticals and Sage Therapeutics enter licensing agreement

Analysis of TIRASMUS data identifies possible marker of temsirolimus efficacy in colorectal cancer

FDA accepts Lymphoseek NDA for review

Further phase I data reported on GDC-941 in metastatic and advanced cancer

New antibacterials show activity against Gram-positive and -negative pathogens

GlaxoSmithKline discloses new RIP-2 inhibitors

New agents for viral infections prepared by Vertex

Novel angiogenesis-promoting peptides patented in Korea

Dosing complete in phase II trial of oral PTH analogue in women with osteoporosis

Amicus closes recruitment in phase III Amigal study

Kinagen claims new protein kinase inhibitors

Promising 96-week data reported from phase II ocrelizumab trial in RRMS

FDA extends PDUFA date for Tysabri sBLA

Findings disclosed from ATON study evaluating atacicept in optic neuritis

Evotec and Apeiron Biologics collaborate on new target

Thrombogenics' ocriplasmin MAA accepted for review

Novel nitroxyl-releasing agents synthesized in U.S.

Isotechnika gives update on Luveniq strategy in Europe

Merck Serono to return full rights to Parkinson's disease candidate to Newron

OncoGenex Pharmaceuticals begins enrollment in OGX-427 study

Critical Outcome Technologies reports promising preclinical data on COTI-2

Protox Therapeutics' study of transrectal PRX-302 advances

EMA finds no link between cancer and use of angiotensin AT receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Sun Pharma to acquire Merck spinoff Organon for $11.75B
BioWorld
Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of...